Literature DB >> 385272

Influence of cigarette smoking on drug metabolism in man.

W J Jusko.   

Abstract

The pervasiveness of tobacco use in our society and the frequency of altered disposition of many common therapeutic and recreational drugs in smokers makes it apparent that the smoking habit should be considered as one of the primary sources of drug interactions in man. Each scientific report dealing with drug disposition should list the smoking status of the subjects studied as smoking should be included as a basic characteristic of each subject along with age, race, body weight, and presence and type of disease. Most of the experimental work in human and animal systems indicates that the dominant effect of smoking is enhanced disposition caused by induction of hepatic microsomal enzymes. The primary causal agents are probably the polynuclear aromatic hydrocarbons which are potent and persistent in tissues. There are numerous examples of both an increased metabolism rate and absence of an effect of smoking on drug disposition in man. This selectivity is consistent with the known inductive effects of P-448 stimulators in animal systems. Studies with theophylline have demonstrated that both tobacco and marijuana markedly alter its clearance in man. However, smoking is only one of numerous factors which can perturb hepatic biotransformation as patient surveillance studies show that age and cardiac and liver disease may be of greater importance in actual patients undergoing therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 385272     DOI: 10.3109/03602537908993892

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  32 in total

1.  Lack of effect of short-term passive smoking on the metabolic disposition of theophylline.

Authors:  D T Casto; B M Schnapf; M A Clotz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Effect of cigarette smoke on pharmacokinetics of oral, intrarectal, or intravenous indomethacin in rats.

Authors:  T Yoshida; Y Gomita; R Oishi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

3.  The effect of a single treatment with cigarette smoke on the blood levels and hemodynamic effects of propranolol in rats.

Authors:  T Berkan; L Ustünes; Z Kerry; M Karol; M Tosun; C Yalçinkaya; A Ozer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jul-Sep       Impact factor: 2.441

Review 4.  Pharmacokinetic drug interactions with oral contraceptives.

Authors:  D J Back; M L Orme
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

5.  Effect of maternal nicotine/thiocyanate exposure during gestational period upon pituitary, thyroid and parathyroid function/morphology of 1-month-old rat offspring.

Authors:  A M Abdelhafez; S A Eltony; S Y Abdelhameed; S A Elgayar
Journal:  J Endocrinol Invest       Date:  2014-03-18       Impact factor: 4.256

Review 6.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

7.  Urinary excretion of mutagens, thioethers and D-glucaric acid in workers exposed to bitumen fumes.

Authors:  R Pasquini; S Monarca; G Scassellati Sforzolini; A Savino; F A Bauleo; G Angeli
Journal:  Int Arch Occup Environ Health       Date:  1989       Impact factor: 3.015

8.  A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.

Authors:  J W Rigby; A K Scott; G M Hawksworth; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

9.  Examining the use of oral contraceptives in the management of acne.

Authors:  Heather L Salvaggio; Andrea L Zaenglein
Journal:  Int J Womens Health       Date:  2010-08-09

Review 10.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Authors:  Mark A Giembycz; Stephen K Field
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.